HC 022
Alternative Names: HC-022Latest Information Update: 29 Oct 2024
Price :
$50 *
At a glance
- Originator HC Biopharma
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Systemic lupus erythematosus
Highest Development Phases
- Research Systemic lupus erythematosus
Most Recent Events
- 29 Oct 2024 HC 022 is available for licensing as of 29 Oct 2024. www.hcbiopharma.com (HC Biopharma website, October 2024)
- 24 Oct 2024 HC Biopharma plans a phase I trial for Systemic lupus erythematosus (In volunteers) in China (SC) in November 2024 (NCT06657703) (CTR20243979)
- 02 Aug 2024 Early research in Systemic lupus erythematosus in Hong Kong (SC) (HC Biopharma Pipeline, August 2024)